Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.

Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). This publication reviews its efficacy and safety, and the limitations of the evidence.

Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with narcolepsy with or without cataplexy (see separate RDTC evaluation).